TKT Announces Date Of Third Quarter 2001 Financial Results and Conference Call
CAMBRIDGE, Mass., Oct 15, 2001 /PRNewswire via COMTEX/ -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX chart, msgs) will release third quarter 2001 financial results on Monday, October 29, 2001 after the close of U.S. financial markets. In connection with this announcement, TKT will host a conference call and live audio webcast on Monday, October 29, 2001 at 5:00 pm EST.
Participants may access the call by dialing 706-679-4323 and referencing the access code 2066083. This call will also be broadcast live over the Internet at www.tktx.com under the events category of the Investor Information section. Please dial in 5 to 10 minutes prior to the scheduled conference call time or log on to the website at least 15 minutes prior to the call in order to register, download, and install any necessary software.
The conference call will be archived on the Internet for approximately 72 hours for those who are unable to hear it live. A replay of the call will also be accessible by telephone after 7:00 pm EST Monday, October 29, 2001 through midnight EST on Thursday, November 1, 2001. To replay the call, dial 706-645-9291 using access code 2066083.
Transkaryotic Therapies, Inc. (TKT) is a biopharmaceutical company dedicated to the development and commercialization of products based on its three proprietary development platforms: Niche Protein(TM) products, Gene- Activated(R) proteins, and Gene Therapy. The Company's Niche Protein product platform is based on protein replacement for the treatment of rare genetic diseases, a group of disorders characterized by the absence of certain metabolic enzymes. TKT's gene activation technology is a proprietary approach to the large-scale production of therapeutic proteins, which does not require the cloning of genes and their subsequent insertion into non-human cell lines. The Company's Gene Therapy technology, known as Transkaryotic Therapy(TM), is focused on the commercialization of non-viral, ex vivo gene therapy products for the long-term treatment of chronic protein deficiency states.
Gene-Activated(R) is a registered trademark and Niche Protein(TM), TKT(TM), and Transkaryotic Therapy(TM) are trademarks of Transkaryotic Therapies, Inc.
Please visit our web site at www.tktx.com for additional information about Transkaryotic Therapies, Inc.
CONTACT:
Daniel E. Geffken
Senior Vice President, Finance
and Chief Financial Officer
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
Source: Transkaryotic Therapies, Inc. (TKT)
Contact:
Daniel E. Geffken, Senior Vice President, Finance and Chief
Financial Officer of Transkaryotic Therapies, Inc., +1-617-349-0581
/Photo: NewsCom: newscom.com
AP Archive: photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
/Company News On-Call: prnewswire.com
URL: tktx.com |
